FY2027 EPS Estimates for Nanobiotix Decreased by Analyst

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) – Equities researchers at HC Wainwright reduced their FY2027 earnings per share estimates for shares of Nanobiotix in a note issued to investors on Monday, March 30th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.37) for the year, down from their previous forecast of ($0.32). The consensus estimate for Nanobiotix’s current full-year earnings is ($1.18) per share. HC Wainwright also issued estimates for Nanobiotix’s FY2029 earnings at $1.21 EPS.

Several other brokerages have also recently weighed in on NBTX. Guggenheim increased their price target on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, April 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, January 22nd. Finally, TD Cowen reiterated a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Nanobiotix Stock Down 9.1%

Shares of NASDAQ NBTX traded down $2.99 during mid-day trading on Tuesday, hitting $29.77. The stock had a trading volume of 49,308 shares, compared to its average volume of 46,772. The business has a 50 day moving average price of $28.52 and a two-hundred day moving average price of $23.73. Nanobiotix has a 1 year low of $2.99 and a 1 year high of $41.89.

Nanobiotix (NASDAQ:NBTX) last announced its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share for the quarter. The business had revenue of $3.42 million during the quarter.

Institutional Trading of Nanobiotix

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Optiver Holding B.V. purchased a new position in Nanobiotix during the 3rd quarter valued at $101,000. Marshall Wace LLP purchased a new position in shares of Nanobiotix during the fourth quarter valued at about $220,000. Royal Bank of Canada increased its position in shares of Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the period. Finally, Millennium Management LLC bought a new position in Nanobiotix in the fourth quarter worth about $390,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.